Randomized, Double-Blind, Pharmacokinetic Equivalence Trial Comparing DRL-Rituximab With MabThera in Patients With Diffuse Large B-Cell Lymphoma

PURPOSE: We sought to compare the pharmacokinetics (PKs) of DRL-rituximab (DRL_RI; potential biosimilar) and innovator rituximab MabThera (Roche, Grenzach-Wyhlen, Germany; reference medicinal product [RMP]) in patients with diffuse large B-cell lymphoma (DLBCL). Efficacy, pharmacodynamics (PDs), saf...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:J Glob Oncol
Asıl Yazarlar: Viswabandya, Auro, Shah, Sandip, Mukhopadhyay, Asis, Nagarkar, Rajnish Vasant, Batra, Sonica Sachdeva, Lopez-Lazaro, Luis, Kankanwadi, Suresh, Srivastava, Alok
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: American Society of Clinical Oncology 2019
Konular:
Original Reports
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC6939748/
https://ncbi.nlm.nih.gov/pubmed/31809224
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JGO.19.00248
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller